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1. Introduction
Hypercholesterolemia is a well-known risk factor for atherosclerosis in adulthood.
In the first years of life atherosclerosis is generally subclinical, but pathological studies
demonstrate that, already in childhood, atherosclerotic vascular changes and their extend are
associated with both the number of cardiovascular risk factors and their intensity [1, 2]. Fatty
streaks and fibrous plaques at autopsy, presence of coronary artery calcium by electron-beam
computed tomography, increased carotid-intima-media thickness, reduced arterial distensi‐
bility and compliance and endothelial dysfunction by ultrasound have been already associated
with lipid abnormalities in youth [3]. Moreover, levels of cholesterol track strongly from
childhood and adolescence over long follow-up period resulting in the progression of
atherosclerosis process and increased cardiovascular disease (CVD) risk [4].
The mechanism by which hyperlipidemia contributes to atherogenesis includes several stages:
• Chronic hyperlipidemia, and especially hypercholesterolemia, might alter endothelial
function, through the increased production of superoxide and other oxygen free radicals,
which deactivate the nitric oxide, the main relaxing factor the endothelium
• During chronic hyperlipidemia, lipoproteins are accumulated in intima increasing endo‐
thelial permeability
• Oxidative modification of lipids, induced by free radicals, leads to the formation of oxidized
low-density-lipoproteins (oxLDL), which, in their turn, are easily phagocyted by macro‐
phages and, consequently, form foam cells. OxLDL are chemotactic for circulating mono‐
cytes, they inhibit the mobility of macrophages already in the lesion, thus, promoting their
recruitment and their persistence in the plaques. They also stimulate the release of growth
factors and cytokines that, in their turn, induce the production of antibodies against oxidized
lipoproteins and cause a chronic inflammation [5, 6]. Such state of chronic or not-resolving
inflammation facilitates lipid accumulation in the atheroma [7].
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In some conditions, characterized by altered lipid assessment or other evident disorders of risk
factors, premature CVD could be manifest in the first decades of life. “Vascular age” is
advanced in 73% of familial dyslipidemic children, independently from the presence of others
atherosclerosis-promoting risk factors [8]. The American Heart Association (AHA), endorsed
by the American Academy of Pediatrics (AAP), identified 8 high-risk pediatric diagnosis and
developed practical recommendations for the management of cardiovascular risk [9]. The
selected diseases comprise familial hypercholesterolemia (FH), together with diabetes mellitus
(type 1 and 2), chronic kidney disease, heart transplantation, Kawasaki disease, congenital
heart disease, chronic inflammatory disease and childhood cancer. Subclinical endothelial
dysfunction, measured through non-invasive surrogate methods such as flow-mediated
dilation (FMD), occurs early in FH children indicating an increased risk for premature CVD
and reflecting the need for early initiation of anticholesterolemic treatment [10]. Moreover,
increasing evidences indicate that, in high-risk conditions as well as in most children with a
minor degree of vascular involvement, appropriate therapy could prevent and/or reverse the
progression of these cardiovascular changes [11, 12]. Therefore, the identification and the
management of hypercholesterolemia in children are of great consequence.
2. Lipid concentrations in childhood and adolescence
The thresholds for defining hypercholesterolemia and elevated low density lipoprotein
cholesterol (LDL-C) in childhood and adolescence are not homogeneous. One set of values
were derived from the National Cholesterol Education Program (NCEP) report (Table 1) [13].
An update, published in 2011, included values of apolipoprotein B (ApoB) and apolipoprotein
A-1 (ApoA-1) coming from the National Health and Nutrition Examination Survey III. NCEP
cutoffs seem to accurately estimate adult values of total cholesterol (TC), LDL-C and trigly‐
cerides (TG), while high lipoprotein cholesterol (HDL-C) levels are better predicted by
National Health and Nutrition Examination Survey (NHANES) cutoff points [14].
Another set of values were derived from the Lipid Research Clinics Prevalence Study [15] and
revised in 2008 by the AAP [16] (Table 2).
The lack of a consensus depends on: lipid variability during infancy, childhood and adoles‐
cence, the subsequent need of using percentiles instead of cut-off values (as used in adulthood)
and the lack of studies that correlate lipid values in childhood with adult cardiovascular risk.
After birth, lipids and lipoproteins gradually increase up to 2 years of life, reaching values
similar to adults: therefore, before the third year of life, the determination of the lipid profile
is neither recommended nor useful. An increased stability with no significant differences
between genders can be observed from 5 to 10 years: until pubertal activation, the use of
reference values proposed by the AAP is recommended [16]. Taking into account the changes
between genders occurring during puberty, the percentiles of reference proposed by Jolliffe
and Janssen for males and females from 12 to 19 years could also be used: these percentiles are
based on studies that correlate the values of lipid profile with the probability of subsequent
clinical cardiovascular risk [17].
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Category Acceptable< 75° p
Borderline
75-90° p
High
> 90°p
TC, mg/dl < 170 170-199 ≥ 200
LDL-C, mg/dl < 110 110-129 ≥ 130
ApoB, mg/dl < 90 90-109 ≥ 110
TG, mg/dl
2-9 y < 75 75-99 ≥ 100
10-19 y < 90 90-129 ≥ 130
HDL-C, mg/dl > 45*(≥25°p)
35-45
(5-25°p)
≤ 35
(≤ 5°p)
ApoA-1, mg/dl >120 110-120 <110
*desiderable: > 65 mg/dl, 75° p
Table 1. Plasma lipid concentration in children and adolescence modified from NCEP, 1992 [13, 14]. Legend: p,
percentile
Male Female
5-9 ys 10-14 ys 15-19 ys 5-9 ys 10-14 ys 15-19 ys
TC, mg/dl
50°p 153 161 152 164 159 157
75° p 168 173 168 177 171 176
90°p 183 191 183 189 191 198
95°p 186 201 191 197 205 208
TG, mg/dl
50°p 48 58 68 57 68 64
75° p 58 74 88 74 85 85
90°p 70 94 125 103 104 112
95°p 85 111 143 120 120 126
LDL-C, mg/dl
50°p 90 94 93 98 94 93
75° p 103 109 109 115 110 110
90°p 117 123 123 125 126 129
95°p 129 133 130 140 136 137
HDL-C, mg/dl
5°p 38 37 30 36 37 35
10° p 43 40 34 38 40 38
25°p 49 46 39 48 45 43
50°p 55 55 46 52 52 51
Table 2. Lipid and Lipoprotein Distributions in Subjects Aged 5 to 19 Years [16]. Legend: p, percentile
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Lipid concentrations vary also according to demographic variables (population specific): TC
seems to be higher among Black children and adolescents than Caucasian ones [18]. Moreover,
dietary habits together with current diseases and seasonality could transitionally influence
cholesterol assessment.
Data from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2006
for  participants  6  to  17 years  of  age documented that  5.2%-6.6% (depending on the cut
points used) and 9.6%-10.7% of them presented an elevated concentration of LDL-C and
TC, respectively [19].
3. Genetic Hypercholesterolemia
Lipid abnormalities can be classified as primary disorders that encompass all genetic (mono‐
genic) forms of dyslipidemia, as summarized in Table 3 [20], and secondary disorders.
Name Genetic Defect Trasmission Clinical features
Classical Familial
Hypercholesterolemia
(FH)
LDLR, diminished
LDL-C clearance
Autosomal
dominant
1:300-1:1.000.000
Heterozygotes: TC 250-500 mg/dl (LDL-C > 135
mg/dl), xanthomas on the extensor tendons of the
hands and feet, arcus cornea and premature CVD
(40-60 y)
Homozygotes: TC 500-1000 mg/dl, xanthomas
and very premature CVD (< 10 y)
Other autosomal
dominant
hypercholesterolemia
PCSK9, diminished
LDL-C clearance
Autosomal recessive
hypercholesterolemia
(ARH)
ARH adaptor protein
absent or unable to
interact with the LDLR,
diminished LDL-C
clearance
Autosomal
recessive
1:100.000
(Sardinia)
Variable, phenotype similar to homozygous FH,
but generally less severe and more responsive to
lipid-lowering therapy, large and bulky
xanthomas from early childhood, TC > 500 mg/dl,
in homozygotes: CVD < 30 y
Familial defective Apo
B-100
Apo B, diminished
LDL-C clearance
Autosomal
dominant
1:700 (North-
Centre Europe)
Heterozygotes: TC 250-500 mg/dl, xanthomas,
arcus senilis and premature CVD (50-60 y)
Homozygotes: TC > 500 mg/dl, premature CVD (<
30 y)
Familial combined
hyperlipidemia Polygenic
Premature CVD, Apo B elevated, TC 250-500
mg/dl, TG 250-750 mg/dl
Beta sitosterolemia Carrier ABCG5/ABCG8
Autosomal
recessive
1:1.000.000
High vegetables sterols and LDL-C
Table 3. Genetic Hypercholesterolemia [20]. Legend: LDLR, low density lipoprotein receptor; PCSK9, proprotein
convertase subtilisin/kexin type 9
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4. Monogenic primary Hypercholesterolemia
Monogenic hypercholesterolemias are lifelong conditions that often present during childhood
and adolescence with clinically and biochemically extreme phenotypes, due to a variety of
gain-of-function or loss-of-function mutations in a range of candidate genes with important
roles in lipid metabolism.
FH is an autosomal dominant monogenic condition. Homozygous familial hypercholestero‐
lemia (HoFH) is rare, with an occurrence of 1:1.000.000 individuals, but the heterozygous state
(HeFH) is present in the general population with an incidence ranging from 1:300 to 1:500. On
this basis we can affirm that HeFH is the most common monogenic disorder in North America
and Europe. Causative FH mutation alters the function of LDL-receptor (LDLR) resulting in a
reduced clearance of LDL-C particles from the circulation and consequently in an elevation of
their plasma levels. In addition to LDLR defects, a similar phenotype can be caused by a
number of mutations in the ApoB gene (that disrupt the binding of the LDL-C particle to the
LDLR) and by gain of function mutations in the proprotein convertase subtilisin/kexin type 9
(PCSK9) gene (that increase LDLR degradation) [21]. So far, more than 1500 variants have been
identified in the LDLR associated with FH, ranging from single-nucleotide substitutions to
large deletions [22]. The clinical presentation of HeFH is characterized by two- to three-fold
elevations in plasma LDL-C levels, by a family history positive for CVD, and, rarely in
childhood, by the presence of physical symptoms of cholesterol deposits in tissues (tendon
xanthomas, xanthelasma palpebrarum). Historically, left untreated, the cumulative risk of
CVD in HeFH patient is greater than 50% in men by the age of 50 years and at least 30% in
women by the age of 60 years. Homozygous and compound heterozygous FH subjects can
experience serious cardiovascular events as early as in childhood: a six- to eight-fold increase
in plasma LDL-C is found in these subjects and severe xanthomatosis and multiple types of
xanthomas could occur.
Most people with FH are undiagnosed or only diagnosed after their first coronary event, but
medical treatment seems to be effective and it could delay or prevent the onset of CVD.
Therefore, early identification of affected individuals is crucial. Cholesterol levels alone are
not sufficient to confirm a diagnosis of FH because of the extensive overlap in LDL–C levels
existing between FH-causing mutation carries and non-carries (non-genetic polygenic
hypercholesterolemia) and the high prevalence of modestly severe LDLR mutations that
hampers the use of LDL-C cut-offs. Therefore, a diagnostic definition of FH, which supports
cholesterol measurements with clinical signs and family history, has become widely used
(Simon Broome Register Group definition of FH) [23]. According to this definition, a “definite”
diagnosis of FH requires:
a. TC level above 260 mg/dl in children under 16 years of age
OR LDL-C levels above 160 mg/dl in children
b. PLUS tendon xanthomas in patient or relative (parent, child, sibling, grandparent, aunt,
uncle)
c. OR DNA-based evidence of an LDLR mutation or familial defective Apo B.
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A “possible” diagnosis of FH is suggested when (a) is present together with one of (d) or (e):
d. family history of myocardial infarction before the age of 50 years in grandparent, aunt,
uncle or before age 60 in parent or siblings
e. family history of raised cholesterol in parents or siblings or levels above 290 mg/dl in
grandparents, aunt or uncle.
A similar diagnostic tool has been developed by the Dutch Lipid Clinic Network. This includes
similar features to the Simon Broome criteria, but adds the calculation of a numeric score [24].
These criteria differ in DNA testing and in their diagnostic effectiveness. In summary, a child
with significant and isolated elevation of LDL-C (≥160 mg/dl) should be considered to have
FH, particularly if there is family history of early CVD.
After diagnosis of FH, cascade screening should occur in all first degree relatives after age 2
years. Cascade screening is a term used to describe searching for affected relatives of an
inherited disorder once an affected person is known. In UK guidelines, DNA-based cascade
testing is recommended in affected families; however, in about 60% of patients no mutations
are found [25]. This finding leads to a great concern: assigning individuals to an “uncertain”
category (when mutation is not identified) is unsatisfactory and provokes confusion and
ambiguity both in children and adults.
After diagnosis, an appropriate treatment should be pursued, especially after CVD risk
assessment, by a lipid specialist.
5. Polygenic forms of Hypercholesterolemia
Dyslipidemia may also result from interaction of synergic environmental and genetic factors
developing the group of multifactorial or polygenic hypercholesterolemia. Because of this
combination of causative factors, biochemical phenotype could be variable: LDL-C and TG
may be high (rarely normal), HDL-C can be normal or reduced and there is significant
production of small, dense LDL-C particles. Contrary to FH, it is less likely to be diagnosed in
children because LDL-C elevation may occur frequently in adolescence, but strongly tracks
into adulthood (70-75% of cases).
6. Secondary Hypercholesterolemia
The prevalence of lipid abnormalities in children is increasing because of the epidemic of
obesity and subsequent metabolic syndrome (MS). Data from 1999-2004 NHANES demon‐
strated that approximately 10% of participants aged 8-19 years had high TC, 7% had low HDL-
C, 9.7% had high TG and 7.6% had high LDL-C. In addition, prevalence of adverse lipid profile
in youths with high adiposity was found significantly greater than participants without it [26].
Low HDL-C, high TG and small dense LDL-C, characterizing the so called “dyslipidemia of
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insulin resistance”, are often associated with obesity and MS [27]. Promoting free-fatty acids
release from visceral fat and altering the hepatic production of apolipoprotein, insulin
resistance (IR) is the ethiological key of dyslipidemia in MS. Recently, the positive association
demonstrated between PCSK9 activity and fasting glucose, insulin and homeostatic model
assessment IR (in addition to lipid levels) suggests that PCSK9 could play a role in the
development of dyslipidemia associated with the MS [28]. Moreover, the endocrine activity of
adipose tissue produces inflammatory cytokines, such as adiponectin and tumor necrosis
factor-alfa, influencing hepatic production of very low density lipoprotein (VLDL). All these
findings highlight the importance to early counteract obesity to prevent the occurrence of
dyslipidemia: the earlier the prevention begins, the better results are achieved.
Secondary dyslipidemia include also those caused by chronic disease, such as diabetes
mellitus, chronic renal insufficiency, hypothyroidism, liver diseases and drugs (e.g. glucocor‐
ticoids, B-blockers, antiretroviral agents) (Table 4).
Clinical features
Obesity Increase TG, decreased HDL-C
Diabetes Mellitus Increase TG and TC, decrease HDL-C
Chronic renal failure Increase TG and TC, decrease HDL-C
HIV/AIDS wasting Increase TG and TC, decrease HDL-C and LDL-C
HIV/AIDS (HAART) Increase TG, TC and HDL-C
Hypothyroidism Increase TG, TC and LDL-C
Nephrotic syndrome Increase TC and LDL-C
Obstructive liver disease Increase TC
Medications Variable
Table 4. Secondary dyslipidemia.
7. Diagnosing Hypercholesterolemia in childhood
In 2011, the National Heart, Lung, and Blood Institute (NHLBI), backed by AAP, proposed an
universal lipid screening to be performed with measurement of non fasting non-HDL-C
(calculated by subtracting the HDL-C from the TC measurement) in all children between ages
9–11 and 17–21 years [14]. The normal variation in blood cholesterol levels within an individual
over time is approximately 6%. Therefore, at least two elevated blood cholesterol measure‐
ments are required in a lapse of time between 15 days and 3 months, before a diagnosis of
hypercholesterolemia can be made. In the remaining groups of age (2-8 and 12-16 years),
NHLBI agrees with the use of selective screening, as proposed by the NCEP [13, 14]: lipid
screening is recommended only in children with positive family history of premature CVD
OR already known familial dyslipidemia OR unknown family history OR presence of multiple
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risk factors such as hypertension, diabetes and obesity OR overweight/obesity alone. Choles‐
terol screening modalities in youth have been debated for decades. The primary goal of
universal screening is to identify those with FH. It has been shown that family history is
incomplete in young individuals, since parents and even grandparents may be too young to
have demonstrated early CVD [29]. The second goal of universal screening is to use cholesterol
assessment to identify children with components of MS in an effort to highlight and prevent
progression of additional components. Nevertheless, there are several critiques that comprise:
the definition of risk-to-benefit ratio, especially regarding moderate dyslipidemia, the
potential risk to determine anxiety in patients and families and, lastly, the financial costs [30].
8. Treatment of Hypercholesterolemia in childhood
In 2010 the AHA, while developing the 2020 Impact Goals, defined the “cardiovascular health”
concept and determined the metrics needed to monitor it over time [31]. In this way the first
step proposed for management of children with identified lipid abnormalities is to assess their
cardiovascular risk. It includes the collection of:
• anamnestic data about familial premature cardiovascular disease (premature means before
55 years of age in males and before 65 in females)
• individual anamnestic risk factors as smoking habit, drugs and the presence of current high
or moderate risk conditions such as hypercholesterolemia, diabetes, Kawasaki disease,
cancer treatment survivors...
• physical examination that include blood pressure and body mass index.
In children, the definition of ideal cardiovascular health includes several goals: avoid smoking,
body mass index less than 85th percentile, more than 60 minutes of moderate- or vigorous-
intensity physical activity every day, health diet, TC values less than 170 mg/dl (6-19 years of
age), blood pressure less than 90th percentile (8-19 years of age) and fasting plasma glucose less
than 100 mg/dl (12-19 years of age) [31].
8.1. Dietary treatment and lifestyle approach
The cornerstone of lipid-lowering therapy is a healthy lifestyle [32].
Dietary recommendations emphasize the following pattern of nutrient intake:
• adequate nutrition should be achieved by eating a wide variety of foods low in saturated
fat and cholesterol
• total caloric intake should be sufficient to support normal growth and development and
maintain desirable body weight
• saturated fatty acids should provide <10% of total calories
• total fat should provide an average of no more than 30% and no less than 20% of total calories
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• polyunsaturated fatty acids should provide up to 10% of total calories
• less than 300 mg of cholesterol should be consumed per day
• children should consume 5 or more daily serving of vegetables and fruits and 6 to 11 daily
servings of whole-grain or other grain foods
• children should eat adequate amounts of dietary fiber (Age + 5 g/day).
All children with LDL-C level >130 mg/dl should receive targeted intervention and follow-up.
The NCEP suggests for hypercholesterolemic patients a two level cholesterol-lowering diet
[13]. In the Step 1 diet (Table 5) approximately 30% of calories derive from fat (10% from
saturated fat) and the total intake of cholesterol should be limited to 300 mg/day. If the lipid
values remain elevated after 6 weeks, the Step 1 diet should be reviewed to increase the
compliance. If the diet for at least 3 months fails to achieve LDL-C concentrations <130 mg/dl
(the ideal goal is to lower it to <110 mg/dl), a more aggressive dietary approach is needed (Step
2 diet). The two main differences between the Step 1 and Step 2 diets are that in the latter, the
amount of saturated fat is reduced to 7% of total calories and the intake of cholesterol is
decreased to 200 mg/day (Table 5). In order to implement this more stringent diet, advice from
a nutritionist trained in dealing with children and disorders of lipids is needed. No restriction
of fat or cholesterol is recommended for infants <2 years of age, when rapid growth and
development require high energy intakes. Dietetic guidelines called Therapeutic Lifestyle
Changes (TLC) replaced Step 1 and 2 diets. For higher risk people they recommended an
adequate caloric intake, including an increased consume of whole grains, low-fat dairy
products, fruits, vegetables and fish and a reduction of soft drinks and salt (Table 5) [33].
STEP 1 STEP 2 TLC diet
Total fats (% of total calories) 30 30 25-35†
Saturated fats
(% of total calories) No more than 10 Less than 7 Less than 7
Dietary Cholesterol (mg/day) Limited to 300 Less than 200 Less than 200
Plants stanols/sterols
(grams per day) NA NA 2
Increased viscous soluble fiber
(grams per day) NA NA 10-25
Legend: †The 25-35% fat recommendation allows for increased intake of unsaturated fat in place of carbohydrates in
people with metabolic syndrome or diabetes.
Table 5. Characteristics and Differences between STEP 1, STEP 2 and TLC diets [33].
The improvement of dietary habits seems to be effective when hyperlipidemia is secondary to
other conditions, such as obesity [34], but it is not sufficient in primary hypercholesterolemia.
Nevertheless, also in the latter dietary restrictions have to be requested, in order to reduce the
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dose of medications and to avoid a further deterioration of the condition. No long-term (up to
10 years) adverse effects on growth and pubertal development have been documented [34-37].
In children with FH and polygenic hypercholesterolemia, additional benefit could derive from
the introduction of soya protein [38] and/or plant stanols and sterol esters (2 g/day) in the diet
[39]. Nevertheless, despite an improvement in TC and LDL-C levels, supplementation with
stanols and sterols does not improve endothelial function, probably because they concomi‐
tantly reduce plasma carotenoids [39]. Recently, a significant reduction of small dense LDL-C
has been demonstrated in 25 hypercholesterolemic children after the introduction in their diet
of a yogurt-drink enriched with 2 gr/day plant sterols [40]. A large amount of sterol could also
derive directly from fruits, vegetables and cereals (see table 6). Therefore, plant stanols and
sterols have to be considered as beneficial, safe, tasteful, easy-accessible and low-cost lipid-
lowering strategy, especially until children at risk become eligible for a more aggressive
therapy.
Food Sterol Content(mg/100 gr edible)
Fruit and vegetables
Broccoli 44
Grean peas 25
Orange 24
Apple 13
Cucumber 6
Tomato 5
Cereals
Wheat bran 200
Swedish knackebrot 89
Wholemeal bread 53
Rolled oats 39
Wheat Bread 29
Fats and Oils
Corn Oil 912
Rapeseed (canola) oil 668
Liquid margarine 522
Sunflower oil 213
Spreadable butter 153
Olive oil 154
Table 6. Sterol content in food.
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The efficacy of a cholesterol-lowering diet, started in childhood, upon reduction of CVD later
in life, has not been firmly established yet [41].
Soluble fibers, including those from psyllium husk, have been shown to increase the choles‐
terol-lowering effects of a low-fat diet. In 2011 guidelines, the water soluble fiber psyllium can
be added to a low fat low-saturated fat diet as cereal enriched with psyllium at a dose of 6
g/d for children 2-12 of age and 12 g/day for those ≥ 12 y of age [14]. Accordingly, it has been
shown that glucomannan, a hydrosoluble fiber, may decrease TC and LDL-C levels, without
changing HDL-C levels, in hypercholesterolemic children [42]. A novel pioneering approach
in reducing the serum cholesterolemia could be represented by the exploitation of probiotics
exerting cholesterol-lowering properties. A recent Italian randomized, double-blind, placebo-
control study evaluates the effects of a probiotic formulation containing three Bifidobacterium
strains on lipid profiles in 39 children affected by primary dyslipidemia: compared to placebo,
probiotics reduced TC by 3.9% and LCL-C by 3.8%. Moreover, this supporting therapy seems
well tolerated [43].
Lifestyle change includes: regular physical activity, screen time less than 2 hours per day,
attainment of ideal body weight (body mass index ≤85th centile for age and gender) and
optimization of blood pressure. In adults the combination of intensive dietary restrictions and
physical exercise improves lipid metabolism, IR and cardiorespiratory fitness, thereby
diminishing cardiovascular risk factors [44]. Reported trials on benefits of physical activity on
lipid-profile are scarce, rarely well—performed and their results are not optimistic. However,
physical activity stimulates lipoprotein lipases and the function of some enzymes like the
lecithin-cholesterol acyltransferase (LCAT), improving HDL-C formation and reducing their
catabolism. Moreover, exercise reduced TG levels and is effective on size and density of LDL-
C particles. Finally, exercise is safe and does not require any additional cost. Therefore, children
should be encouraged to undertake 60 minutes or more of vigorous aerobic activity per day.
The TLC diet itself recommends expending at least 200 kcal per day [33]. The abuse of tobacco
and alcohol should be avoided. An early identification and correction of eating disorders
should be recommended.
8.2. Pharmacological treatment
If cholesterol does not reach acceptable levels through diet, the recourse to a pharmacological
treatment is allowed and advised [45]. The NCEP recommends the administration of medica‐
tions only to children > 10 years of age (better if either at pubertal Tanner stage II or higher or
after onset of menses in girls) and only when an aggressive diet lasting at least 6-12 months
fails [13]. A lipid specialist should be consulted. Traditionally, bile acid sequestrants (BAR)
were considered the first-line therapy in hypercholesterolemic children. Since AHA statement,
statins replaced BAR: their use is now recommended in children younger than 10 years of age
(from 8 years of age). Surprisingly, AAP encouraged the application of this revised therapeut‐
ical approach [16] causing many controversies among experts: up to now, the efficacy of statins
on adult-onset of CVD is not clearly defined and data about their long-term safety, particularly
because they interfere with the production of steroid hormones and liver function, are still
lacking. Nevertheless, in 2002-2005, the use of lipid-lowering drugs increased in children by
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15% [46] and the American Food and Drug Administration (FDA) and the European Medicines
Agency (EMEA) approved pravastatin in children > 8 years, while simvastatin, lovastatin and
atorvastatin were registered by the FDA for children > 10 years of age. Ezetimibe was also
approved by the FDA and EMEA for pediatric use from the age of 10 years.
8.3. 3-Hydroxy-3-MethylGlutaryl-CoA (HMG-Coa) reductase inhibitors
Statins inhibit HMG-CoA reductase, an enzyme fundamental in de novo cholesterol synthesis.
Their action consequently provokes an increase in hepatic production of LDLR determining
an additional decrease in LDL-C levels. Statins are commonly safe and well tolerated. How‐
ever, because of the principal role of cholesterol in cellular structure and function, the use of
statins is not allowed in prepubertal children. In HeFH children and adolescents, statins are
effective in reducing levels of LDL-C by 20-40% and increasing HDL-C, but, because of the
scarcity and the non-uniformity of trials shown by meta-analysis, no data about outcomes of
different types, doses and length of therapy could be deduced [47,48]. In terms of safety, no
differences in occurrence of adverse effects, alterations in sexual development and muscle or
liver toxicity have been demonstrated in children treated with statins in comparison to placebo-
treated ones [49]. Nevertheless, while adult guidelines do not recommend routine screening
of liver and muscle enzymes during treatment, pediatric guidelines indicate to start statin at
the lowest dose with baseline measurements of alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and creatinine kinase (CK). These levels plus a fasting lipid profile
should be repeated four and eight weeks after initiation of therapy and then every 3–6 months.
If liver enzymes are above 3 times the upper limit of normal and/or CK is above 10 times the
upper limit of normal and/or patient complains any adverse effects, medication should be
stopped to determine if there is an improvement. Some researchers have suggested hydro‐
philic statins, such as fluvastatin, rosuvastatin and pravastatin are less potentially toxic than
lipophilic statins, such as atorvastatin, lovastatin, and simvastatin; the risk of myopathy was
suggested to be lowest with pravastatin and fluvastatin, probably because they are more
hydrophilic [50].
Up to now, few studies have examined vascular efficacy of statins in children, confirming an
increase of impaired FMD before and a significant improvement after treatment [11, 51], long-
term effects have been less studied [52]. Recently, secretory phospholipase A2-IIA (sPLA2-IIA)
receives increased interest because of its role in the inflammatory process of atherosclerosis: it
induce LDL-C modification, foam cell formation and activation of various immune mecha‐
nisms. Published data demonstrated no effects of 2-years-long pravastatin therapy in reducing
sPLA2-IIA mass or sPLA2 activity levels in 91 FH children compared to placebo [53].
Statins are contraindicated during pregnancy because of potential teratogenic risk. Because of
this concern, statins should be used to treat adolescent FH females only if they are aware of
the risk, under a close follow-up and on contraceptive therapy when indicated.
Target LDL-C is typically below 130 mg/dl, but ideally under 100 mg/dl in high risk popula‐
tions such as FH. If target levels are not achieved within 3 months, the dose of statin can be
gradually increased to maximum dose. Occasionally, a second agent such as a BAR may be
useful. Multiple drug therapy should be guided by a lipid specialist.
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8.4. BAR
Even if FDA never approved BARs in children, they were used in the past as first-line therapy
in hypercholesterolemia. Colestipol, cholestyramine and colestilan bind bile salts in the
intestine preventing their re-absorption and increasing their excretion and discharge from
cholesterol pool. Increased emission of bile acids causes a large conversion of cholesterol into
bile salts; in liver, cholesterol pool decreases and a compensatory rise in LDLR synthesis takes
place. In children with HeFH, BARs determine a decrease in TC of 10-20%. These drugs are
not absorbed systematically, but local side-effects as abdominal pain and nausea could nullify
compliance. Recently, a novel bile acid sequestrant, the colesevelam hydrochloride, with
enhanced binding capacity for bile acids has been evaluated in HeFH children, alone or in
combination with statin therapy: the therapeutical compliance has increased (about 85%)
together with an effective LDL-C reduction [54].
8.5. Niacin and fibrates
Niacin, a water-soluble B complex vitamin, increases HDL-C levels and significantly reduces
hepatic production and release of VLDL but it is not commonly utilized in children because
of lack of information about its safety. Adverse effects consist of flushing, hepatic insufficiency,
myopathy, glucose intolerance and hyperuricemia. Therefore, niacin is limited both in HoFH
children and in ones with stroke and increased lipoprotein A levels.
Fibrates (gemfibrazil, fenofibrate, bezafibrate and ciprofibrate) are mainly effective in lowering
TG and in increasing HDL-C, while LDL-C levels seem only partially and variably influenced.
They have a complex and poorly understood way of action and, due to the lack of data on
safety, their use is restricted in HeFH children with high TG levels and an increased risk for
pancreatitis.
8.6. Ezetimibe
Ezetimibe is a new selective cholesterol absorption inhibitor acting at the brush border of
the small intestine with no effects on the absorption of TG and fat-soluble vitamins. Target
pathways  may  consist  in  the  Niemann-Pick  C1-like  protein  and  the  annexin-caveolin  1
complex. In 2002, FDA approved ezetimibe in FH children older than 10 years of age, but
long-term effects have not been extensively evaluated yet. In HoFH, ezetimibe has a synergic
effect  in  reducing  LDL-C,  if  associated  with  statins,  without  increasing  adverse  effects.
Satisfying data in term of efficacy and tolerance have also been documented in children
with polygenic hypercholesterolemia, HeFH and familial combined hyperlipidemia treated
with ezetimibe [55].
These positive data are partially dampened by an absolute lack of knowledge about the long-
term effects of ezetimibe. In fact, the combination of statin and ezetimibe may not restore
endothelial dysfunction [56]. Moreover, ezetimibe dose not influence HDL-C, an independent
risk factor for CVD. Future data from the ongoing IMPROVED-IT study, enlisting 18.000 adults
affected by acute coronary syndrome on simvastatin either with or without ezetimibe, may
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clarify the role of ezetimibe in CVD prevention [57]. In addition, systemic effects of ezetimibe,
in contrast to its minimal absorption have still to be clearly defined.
In the last years, new lipid-lowering drugs are coming out. Starting from the demonstration
that PCSK9 loss-of-function mutations result in a significant drop in circulating LDL-C,
subsequent studies demonstrated that PCSK9 binds the epidermal growth factor precursor
homology domain-A on the surface LDLR and directs LDLR and PCSK9 for lysosomal
degradation. A monoclonal antibody that binds circulating PCSK9 and blocks its interactions
with surface LDLR and called Alirocumab has recently demonstrated a great potentiality in
reducing LDL-C in adulthood. Nevertheless, there is no data in adolescence and no evidence
on its capacity in improving CVD outcome yet [58].
9. HoFH: Treatment in childhood
HoFH has to be considered an almost exclusive pediatric disease. Because of the earlier risk of
CVD, HoFH patients should started pharmacological therapy as soon as possible, as recom‐
mended by AHA [45]. LDL-C apheresis and/or liver transplant have been the historical
treatment in this subset, although efficacy and success are variable [59]. LDL-C apheresis is an
extracorporeal plasma-perfusion method that involves selective removal of LDL-C particles.
The procedure takes three or more hours and is performed at 1- to 2-week intervals. Even if it
results in the regression of coronary lesions and has been found to increase life expectancy, its
use is limited by its availability, higher cost and difficulties in procedures [60]. As most of the
LDLR are present in the liver, liver transplantation alone or in combination with pharmaco‐
therapy is effective in normalizing the plasma cholesterol levels. Nevertheless, the associated
risks include the need of a life-long immunosuppressive therapy [61]. HoFH may also benefit
from lipid-lowering drugs. However, statins require some residual LDLR function, thus they
are not effective in receptor-negative HoFH. Higher risk patients will benefit from combination
therapy: ezetimibe, but also niacin, fibrates, and BAR. Therapeutic efficacy, safety, medication
adherence, and compliance should be monitored closely. Novel medical therapies for adults
with HoFH have recently been approved in the US. These include inhibitors of PCSK9,
microsomal triglyceride transfer protein and cholesteryl ester transfer protein (CETP), as well
as mipomersen, an apolipoprotein B synthesis inhibitor [62, 63].
10. Conclusions
The role of pediatrician in the prevention of chronic and disabling diseases in adulthood is
reinforced by the extensive scientific evidence that proves the beginning of causative processes,
such as atherosclerosis, in childhood. Therefore, the identification of patients at risk of
premature CVD has become, today, one of the primary aims of pediatricians. The evaluation
of hypercholesterolemic children should not be based exclusively on lipid assessment: it is
essential to quantify the overall cardiovascular risk through the collection of a full medical
history (including familial history), the performance of an accurate physical examination, the
assessment of eating habits and the identification of concomitant risk factors. Moreover, in
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hypercholesterolemic children, the monitoring over time of cardiovascular function through
non-invasive methods can be useful.
Childhood could be considered as the best period of life to acquire a proper lifestyle and
healthy eating habits, especially in patients at risk of premature CVD. The diet, low in saturated
fat and cholesterol, should be the first therapeutic approach to be proposed in children with
hypercholesterolemia. Early pharmacological treatment could be planned in cases of genetic
hypercholesterolemia or when diet alone persistently fails. Several studies have demonstrated
the short-term efficacy and safety of statins in childhood.
The definition of pediatric population-specific percentiles for lipid values, the achievement of
a shared screening strategy and the demonstration of long-term safety and efficacy of statin
therapy have to be considered the current priorities for improving the approach to childhood
hypercholesterolemia.
Nomenclature
AHA; American Heart Association
AIDS; Acquired Immune Deficiency Syndrome
ALT; Alanine aminotransferase
Apo; Apolipoprotein
AAP; American Academy of Pediatrics
AST; Aspartate aminotransferase
BAR; Bile acid sequestrants
CK; Creatine phosphokinase
CVD; Cardiovascular disease
EMEA; European Medicines Agency
FDA; Food and Drugs Administration
FH; Familial Hypercholesterolemia
FMD; Flow-mediated dilation
HAART; Hightly active antiretroviral therapy
HDL; High-density lipoprotein
HDL-C; High-density lipoprotein cholesterol
HeFH; Heterozygous familial hypercholesterolemia
HIV; Human immunodeficiency virus
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HMG-CoA; 3-Hydroxy-3-MethylGlutaryl-CoA
HoFH; Homozygous familial hypercholesterolemia
IR; insulin resistance
LCAT; Lecithin-cholesterol acyltransferase
LDL; Low-density lipoprotein
LDL-C; Low-density lipoprotein cholesterol
LDLR; Low-density lipoprotein receptor
MS; Metabolic syndrome
NCEP; National Cholesterol Education Program
NHANES; National Health and Nutrition Examination Survey
NHLBI; National Heart, Lung, and Blood Institute
oxLDL; oxidized low-density lipoprotein
PCSK9; Proprotein convertase subtilisin/kexin type 9
sPLA2-AII; Secretory phospholipase A2-IIA
TC; Total cholesterol
TG; Triglycerides
TLC; Therapeutic lifestyle change
VLDL; Very low density lipoprotein
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